Ocugen (OCGN) Other Non-Current Liabilities (2016 - 2026)
Ocugen's (OCGN) quarterly Other Non-Current Liabilities came in at $3.0 million in Q1 2026, up 415.01% YoY from $573000.0 in Q1 2025, and up 84.09% on a QoQ basis from $1.6 million in Q4 2025.
Powered by 
Analysis
Ocugen (OCGN) Other Non-Current Liabilities (2016 - 2026) Analysis & Trends
Ocugen (OCGN) has 10 years of Other Non-Current Liabilities data on file, last reported at $3.0 million in Q1 2026.
- Quarterly Other Non-Current Liabilities rose 415.01% year-over-year to $3.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.0 million (up 415.01% YoY) and the FY2025 annual result came in at $1.6 million, up 184.22% from the prior year.
- Other Non-Current Liabilities climbed to $3.0 million in Q1 2026, from $1.6 million in the prior quarter.
- In the past five years, Other Non-Current Liabilities ranged from a high of $3.0 million in Q1 2026 to a low of $244000.0 in Q4 2022.
- A 5-year average of $823857.1 and a median of $549500.0 in 2024 frame the typical range for Other Non-Current Liabilities.
- Annual changes were most pronounced in 2025 — Other Non-Current Liabilities climbed 6.9% — and 2026, when it soared 415.01%.
- Tracing OCGN's Other Non-Current Liabilities over 5 years: stood at $244000.0 in 2022, then surged by 115.98% to $527000.0 in 2023, then grew by 7.02% to $564000.0 in 2024, then surged by 184.22% to $1.6 million in 2025, then jumped by 84.09% to $3.0 million in 2026.
- The last three Other Non-Current Liabilities figures came in at $3.0 million (Q1 2026), $1.6 million (Q4 2025), and $1.6 million (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Ocugen | 458.91 Mn | 358.81 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 33.71 Mn |
| Mar 31, 2026 | 2.95 Mn |
| Dec 31, 2025 | 1.60 Mn |
| Sep 30, 2025 | 1.59 Mn |
| Jun 30, 2025 | 583,000.00 |
| Mar 31, 2025 | 573,000.00 |
| Dec 31, 2024 | 564,000.00 |
| Sep 30, 2024 | 554,000.00 |
| Jun 30, 2024 | 545,000.00 |
| Mar 31, 2024 | 536,000.00 |
| Dec 31, 2023 | 527,000.00 |
| Sep 30, 2023 | 497,000.00 |
| Jun 30, 2023 | 455,000.00 |
| Mar 31, 2023 | 309,000.00 |
| Dec 31, 2022 | 244,000.00 |
| Mar 31, 2020 | 3,940.00 |
| Dec 31, 2019 | 9,755.00 |
| Jun 30, 2019 | 15,000.00 |
| Mar 31, 2019 | 10,000.00 |
| Dec 31, 2018 | 37,459.00 |